Medidata, Cognizant form strategic alliance to empower digital transformation

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/BsWei)
(Image: Getty/BsWei)

Related tags: Medidata, Cognizant, Data

Medidata is working with Cognizant to develop a set of services that will provide pharma, biotech, CROs and others with the capabilities to “digitally transform” their research and commercialization.

Medidata and Cognizant have formed a multi-year strategic alliance to develop new solutions for pharmaceutical, biotech, medical device companies, contract research organizations (CROs), sites, and investigators.

Scott Hoffman, senior vice president, global services, solutions and alliances at Medidata, said the goal is to “empower life science organizations of all sizes and therapeutic areas to digitally transform their research and commercialization.”

“As clinical trials become more complex, the key to success is eliminating operational burdens so that researchers can focus on the science of a study,”​ he told us.

Under the agreement, the professional services company Cognizant will develop managed services and solutions specific to Medidata’s platform. As part of this, Medidata Site Payments also will connect with Cognizant’s Shared Investigator Platform (SIP).

Hoffman explained that the combination of professional services with technology and data assets will remove operational barriers, enabling sponsors and CROs to optimize and expand their studies.

“For example, some sponsors and CROs may hesitate to adopt a modern randomization and trial supply management (RTSM) solution without built-in services such as biostats, drug supply management and help desks,”​ he said.

“Wrapping Cognizant services around Medidata’s RTSM solution eliminates this challenge and drives adoption of this critical tool for improving data quality and reducing risk.”

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more